產品描述: | ARV-771 是一種有效的 pan-(bromodomain and extra-terminal)BET 降解劑,一種新型的BET-PROTAC(proteolysis-targeting chimera),對于BRD2(1)、BRD2(2)、BRD3(1)、BRD3(2)、BRD4(1) 和 BRD4(2)的Kd值分別為34 nM、4.7 nM、8.3 nM、7.6 nM、9.6 nM 和 7.6 nM。 |
靶點: |
BRD2-BD2(Cell-free assay):4.7 nM(Kd); BRD3-BD2(Cell-free assay):7.6 nM(Kd); BRD4-BD2(Cell-free assay):7.6 nM(Kd); BRD3-BD1(Cell-free assay):8.3 nM(Kd); BRD4-BD1(Cell-free assay):9.6 nM(Kd); BRD2-BD1:34 Nm;EpigeneticReaderDomain |
體外研究: |
ARV-771 is a potent small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition. ARV-771 treatment of CRPC cells results in apoptosis |
體內研究: |
ARV-771 induces degradation in vivo. ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model. |
細胞實驗: |
Cell lines: 22Rv1 cells, VCaP cells, LnCaP95 cells Concentrations: 1-300 nM Incubation Time: 24 h, 72 h Method: c-MYC ELISA. 22Rv1 cells (30,000 cells per well) were dosed with ARV-771 serially diluted at 1:3 ratio for an eight-point dose curve. AR ELISA. VCaP cells (40,000 cells per well) were dosed with ARV-771 serially diluted at 1:3 ratio for an eight-point dose curve. Cell Proliferation Assay Protocol. 22Rv1 cells (5,000 cells per well) were dosed with ARV-771 serially diluted 1:3 for a 10-point dose curve for 72 h. |
動物實驗: |
Animal Models: Mice implanted subcutaneously with 5 × 106 22Rv1 or VCaP cells Dosages: 30 mg/kg Administration: IH/SC |
參考文獻: |
1. Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
1.014 ml |
5.068 ml |
10.135 ml |
5 mM |
0.203 ml |
1.014 ml |
2.027 ml |
10 mM |
0.101 ml |
0.507 ml |
1.014 ml |
50 mM |
0.02 ml |
0.101 ml |
0.203 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |